Abstract 4385
Background
For cancer prevention and early diagnostics oncological awareness of the ordinary people is crucial. The knowledge of the problem is extremely important in young population. The aim of the study was to assess the basic oncological knowledge of high school students.
Methods
The study was conducted among high school students in Olsztyn in Poland between April 2017 and April 2018. It was a part of a health promotion program focused on oncological education for high school students in Warmia and Mazury District. The examination was carried out at the beginning of lectures conducted by medical students. The respondents filled in a questionnaire especially prepared for this study. Participation in the study was voluntary and anonymous. The chi-square test was used to compare the subgroups. A p-value <0.05 was considered significant. Statistical analysis was done using STATISTICA software 13.1 (Statsoft, Poland).
Results
The study was done on 227 students (age 17-18 years) from 5 high schools in Olsztyn. There were 125 female and 101 male (one unknown). Almost 80% of responders could correctly defined cancer disease. 153 students (67%) believed genetic predispositions to be the greatest factor affecting cancer morbidity. At the same time, 183 responders (81%) claimed that people have an impact on cancer development. But only 19% students indicated smoking as an important cancerogenous factor and none alcohol. Diet and physical activity influence on cancer prevalence were known only by 5 and 2 students, respectively. Over half of students (58%) thought they lead a healthy lifestyle, but almost 1/3 respondents smoke cigarettes. All students except eight (97%) believed that early detected cancer can be successfully treated. There was no difference depending on sex and place of residence in all questions.
Conclusions
The impact of genetic predispositions in neoplastic diseases seems to be overestimated by high school students. Students knew that lifestyle has an impact on cancer disease, but they did not associate smoking, alcohol, diet, physical activity with a healthy lifestyle. There is a need for more education about cancer and its’ prophylactic among high school students in Poland.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract